Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

• Type: Article in National Scientific Journal
• Date: 2021

Authors

Danila, E (Author) Other; Mariandyshev, A (Author) Other; Shrestha, B (Author) Other; Lukhele, N (Author) Other; Dalcolmo, M (Author) Other; Shakya, SR (Author) Other; Miliauskas, S (Author) Other; Kuksa, L (Author) Other; Manga, S (Author) Other; Aleksa, A (Author) Other; Denholm, JT (Author) Other; Khadka, HB (Author) Other; Skrahina, A (Author) Other; Diktanas, S (Author) Other; Ferrarese, M (Author) Other; Bruchfeld, J (Author) Other; Koleva, A (Author) Other; Piubello, A (Author) Other; Koirala, GS (Author) Other; Udwadia, ZF (Author) Other; Palmero, DJ (Author) Other; Munoz Torrico, M (Author) Other; Gc, R (Author) Other; Gualano, G (Author) Other; Grecu, VI (Author) Other; Motta, I (Author) Other; Papavasileiou, A (Author) Other; Li, Y (Author) Other; Hoefsloot, W (Author) Other; Kunst, H (Author) Other; Mazza Stalder, J (Author) Other; Payen, MC (Author) Other; Akkerman, OW (Author) Other; Bernal, E (Author) Other; Manfrin, V (Author) Other; Matteelli, A (Author) Other; Hamdan, HM (Author) Other; Marcos, MN (Author) Other; Loidi, JC (Author) Other; Gallardo, JJC (Author) Other; Duarte R (Author) FMUP; Salinas, NE (Author) Other; Rosso, RG (Author) Other; Laniado Laborin, R (Author) Other; Robles, EM (Author) Other; Fernandez, SQ (Author) Other; Rendon, A (Author) Other; Solovic, I (Author) Other; Tadolini, M (Author) Other; Viggiani, P (Author) Other; Belilovski, E (Author) Other; Boeree, MJ (Author) Other; Cai, Q (Author) Other; Davidaviciene, E (Author) Other; Forsman, LD (Author) Other; De Los Rios, J (Author) Other; Draksiene, J (Author) Other; Duga, A (Author) Other; Elamin, SE (Author) Other; Filippov, A (Author) Other; Garcia, A (Author) Other; Gaudiesiute, I (Author) Other; Gavazova, B (Author) Other; Gayoso, R (Author) Other; Gruslys, V (Author) Other; Jonsson, J (Author) Other; Khimova, E (Author) Other; Madonsela, G (Author) Other; Magis Escurra, C (Author) Other; Marchese, V (Author) Other; Matei, M (Author) Other; Moschos, C (Author) Other; Nakceriene, B (Author) Other; Nicod, L (Author) Other; Palmieri, F (Author) Other; Pontarelli, A (Author) Other; Smite, A (Author) Other; Souleymane, MB (Author) Other; Vescovo, M (Author) Other; Zablockis, R (Author) Other; Zhurkin, D (Author) Other; Alffenaar, JW (Author) Other; Caminero, JA (Author) Other; Codecasa, LR (Author) Other; Garcia Garcia, JM (Author) Other; Esposito, S (Author) Other; Saderi, L (Author) Other; Spanevello, A (Author) Other; Visca, D (Author) Other; Tiberi, S (Author) Other; Pontali, E (Author) Other; Centis, R (Author) Other; D'Ambrosio, L (Author) Other; van den Boom, M (Author) Other; Sotgiuw, G (Author) Other; Migliori, GB (Author) Other; Koirala, S (Author) Other; Borisov, S (Author) Other

Journal

Title: Pulmonology

ISSN: 2531-0429

Publisher: Taylor & Francis

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Other information

Authenticus ID: P-00T-RSF

DOI: 10.1016/j.pulmoe.2021.02.006

Abstract (EN): The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up. (C) 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10